Small doses (1-10 vg daily) of 24,25-dihydroxycholecalciferol (24, 
Introduction
Vitamin D,, derived from the diet or by the action of ultraviolet light on the skin, undergoes metabolic conversion before exerting its biological effects. ' Intestinal calcium absorption was measured in 17 normal subjects and 13 patients with chronic renal failure treated by long-term haemodialysis (Kiil Multipoint dialyser, 12-18 h/week). Seven of these patients were anephric. Six additional patients, who did not have chronic renal failure but had various other disorders of mineral metabolism, underwent metabolic balance studies. None of the patients had taken vitamin D or anticonvulsant drugs for at least six months before the present study.
In all normal subjects and patients with chronic renal failure calcium absorption was assessed on a total body counter2'i by the seven-day retention of an oral dose of 7 Ca given with 200 mg calcium as the gluconate. The patients and normal subjects fasted at least four hours before and two hours after the test dose. On completion of the first absorption test they were given the agent to be tested for seven days. A second and similar dose of 47Ca was given on the fourth day of treatment. Thus each evaluation comprised two separate determinations of calcium absorption. In four of the anephric patients and seven normal subjects a third calcium absorption test was done three days after stopping treatment to assess the duration of any response. The patients with chronic renal failure were always given the dose of 47Ca at the same time in relation to their next dialysis treatment. The total body retention of 47Ca was not corrected for losses of 4'Ca into the dialysate fluid or the urine, since these losses were too small to be measured accurately. The agents tested were 1,25-(OH)2D, or 24,25-(OH)2D3, 1-2 .rg (2 4-4-8 nmol) given daily by mouth for seven days. Several of the patients and normal subjects had their responses measured more than once (table I), but in each case a new baseline measurement of calcium absorption was made, and at least 14 days elapsed between treatments. Four of the patients and 13 normal subjects also underwent two calcium absorption tests but without administration of vitamin D metabolites between to assess the random fluctuations in the test.
Metabolic balances of calcium and inorganic phosphate were measured in the six patients without chronic renal failure who had various other disorders of mineral metabolism (see table II). Copper thiocyanate and carmine red were used as internal and external markers respectively.27 The diet prescribed was as close as possible to the patients' normal intake of calcium and phosphate and this was checked by regular analysis of samples of the diet. After four days of fig 2) .
Six of the normal subjects subsequently took the pure R form of 24,25-(OH)2D3, and their mean calcium absorption increased from 17 5+2-50 to 22-5±1-7 % (P<0-02). Comparison between the efficacy of the two batches of 24,25-(OH)2D, showed no difference in the mean increment noted (mean increment (+ SE of mean) 24R, + 5-0+1-2%; 24R+S, + 6-1+1-8%).
In the six anephric patients given 24,25-(OH)2D3 calcium absorption also increased during its administration (from 105+18% to 242 +6±9 ; fig 2) to levels found in healthy people (fig 1) .
Calcium absorption was measured three days after stopping 24,25-(OH)2D3 in four anephric patients and seven normal subjects. Absorption of 47Ca, which had increased during the treatment period, fell thereafter to pretreatment levels ( fig 3) .
Using the same protocol, calcium absorption was measured in five normal subjects and 11 patients with chronic renal failure on maintenance haemodialysis (five anephric) before and during the administration of 1,25-(OH)2D3 (1 stg daily) by mouth. Calcium absorption increased in all groups (fig 2) and the increment noted in *The nomenclature refers to the spatial position of the 24-hydroxyl group on 'the side chain of vitamin D3. The R form is thought to be the epimer that is produced biologically. Another patient (case 5) who was given 2 ,ug for two four-day periods also showed no change in absorption or balance of calcium, whereas a subsequent study using 1,25-(OH)2D3 (2 Ftg daily for 8 days)
produced a considerable increase in calcium balance (from -2 6 to +-3-3 mmol/day (-104 to +132 mg/day)).
In two patients (cases 2 and 3) in whom balance studies were continued after stopping 24,25-(OH)2D,, the net absorption and the (fig 5a and c) , despite comparable increases in the net intestinal absorption of calcium with each of the compounds.
PLASMA AND URINARY PHOSPHATE
Plasma phosphate concentrations, measured in the balance studies, did not change consistently (mean ±SE of mean before, 1-09±0-13 mmol/l (3-4±0-4 mg/100 ml); after, 1-11±0-16 mmol/l (34±0t5 mg/100 ml). Mean urinary phosphate did not change significantly but in some patients it fell slightly (table II and fig 4) 
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promoting calcium retention in patients with bone-losing states such as osteoporosis.
Introduction
Ensuring that patients comply with their therapeutic regimen is a major problem in the long-term treatment of hypertension, especially if they are free of symptoms. The simpler the regimen the easier it should be for patients to comply. We describe a study performed to investigate whether the same degree of :3-blockade and blood pressure control could be obtained throughout the day with a once-daily dose of the p-blocking agent metoprolol as with a thrice-daily regimen.
